Aerovate Therapeutics (AVTE)
(Delayed Data from NSDQ)
$1.94 USD
+0.04 (2.11%)
Updated Sep 5, 2024 04:00 PM ET
After-Market: $1.93 -0.01 (-0.52%) 7:58 PM ET
2-Buy of 5 2
D Value D Growth F Momentum F VGM
Cash flow Statements
Fiscal Year End for Aerovate Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -75.52 | -51.51 | -22.96 | -9.61 | -3.33 |
Depreciation/Amortization & Depletion | -2.96 | -0.84 | 0.03 | 0.00 | 0.00 |
Net Change from Assets/Liabilities | 9.80 | 7.76 | -6.51 | 0.97 | 0.55 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 11.91 | 5.48 | 2.04 | 0.78 | 0.00 |
Net Cash From Operating Activities | -56.78 | -39.12 | -27.40 | -7.86 | -2.78 |
Property & Equipment | -0.14 | -0.20 | -0.18 | 0.00 | 0.00 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 12.02 | 7.12 | -113.25 | 0.00 | 0.00 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 11.88 | 6.93 | -113.43 | 0.00 | 0.00 |
Uses of Funds
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 46.23 | 0.77 | 190.46 | 6.42 | 0.00 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 2.50 | 2.50 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.23 | -0.37 | 0.00 | 0.00 | 0.00 |
Net Cash from Financing Activities | 46.00 | 0.40 | 190.46 | 8.92 | 2.50 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 1.09 | -31.80 | 49.62 | 1.06 | -0.28 |
Cash at Beginning of Period | 22.40 | 54.20 | 4.57 | 3.51 | 3.80 |
Cash at End of Period | 23.49 | 22.40 | 54.20 | 4.57 | 3.51 |
Diluted Net EPS | -2.87 | -2.10 | -1.87 | -40.31 | NA |
Fiscal Year End for Aerovate Therapeutics, Inc falls in the month of December.
All data in Millions except Per Share data.
Cash Flow From Operations, Investments & Financial Activities
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Cash Flow From Operations, Investments & Financial Activities |
|||||
Net Income (Loss) | -47.96 | -23.19 | -75.52 | -55.11 | -35.55 |
Depreciation/Amortization & Depletion | -1.40 | -0.73 | -2.96 | -2.05 | -1.27 |
Net Change from Assets/Liabilities | -2.82 | -3.96 | 9.80 | 6.53 | 5.03 |
Net Cash from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Operating Activities | 8.07 | 4.20 | 11.91 | 8.66 | 5.42 |
Net Cash From Operating Activities | -44.11 | -23.67 | -56.78 | -41.98 | -26.37 |
Property & Equipment | 0.00 | 0.00 | -0.14 | -0.08 | -0.05 |
Acquisition/ Disposition of Subsidiaries | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investments | 26.83 | 8.83 | 12.02 | 6.31 | 19.40 |
Other Investing Activities | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Cash from Investing Activities | 26.83 | 8.83 | 11.88 | 6.23 | 19.36 |
Uses of Funds
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | |
---|---|---|---|---|---|
Issuance (Repurchase) of Capital Stock | 25.16 | 0.70 | 46.23 | 45.77 | 45.67 |
Issuance (Repayment) of Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Increase (Decrease) Short-Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Payment of Dividends & Other Distributions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Financing Activities | -0.31 | -0.23 | -0.23 | -0.23 | -0.16 |
Net Cash from Financing Activities | 24.85 | 0.47 | 46.00 | 45.53 | 45.51 |
Effect of Exchange Rate Changes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Change In Cash & Equivalents | 7.58 | -14.37 | 1.09 | 9.78 | 38.50 |
Cash at Beginning of Period | 23.49 | 23.49 | 22.40 | 22.40 | 22.40 |
Cash at End of Period | 31.07 | 9.12 | 23.49 | 32.18 | 60.90 |
Diluted Net EPS | -0.86 | -0.83 | -0.73 | -0.71 | -0.76 |